ASCO 2021 | Bispecific antibodies in lung cancer
Benjamin Besse, MD, PhD, Gustave Roussy Cancer Institute, Paris, outlines the role of bispecific antibodies in treating lung cancer. Bispecific antibodies can have two different targets on the same cancer cell such as amivantamab, which targets EGF and MET receptors in patients with non-small cell lung cancer (NSCLC). Bispecific antibodies can alternatively bind to a cancer cell and an immune cell simultaneously but have stronger side effects compared to other approaches. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Benjamin Besse, MD, PhD has received sponsored research funds from 4D Pharma, Abbvie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Inivata, Janssen, Onxeo, OSE immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals.
